Utilization and outcomes of palliative therapy for hepatocellular carcinoma: A population-based Study in the united states

Journal of Clinical Gastroenterology

Volumn 46, Issue 1, 2012, Pages 71-77

  Davila, Jessica A ^a   Duan, Zhigang ^a   Mcglynn, Katherine A ^b   El Serag, Hashem B ^a,c  

^a Section of Health Services Research   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c NCI/DHHS   (United States)

Author keywords

Chemotherapy; Hepatocellular carcinoma; Palliative treatment

Indexed keywords

ARSENIC TRIOXIDE; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLOXURIDINE; FLUOROURACIL; GEMCITABINE; GOSERELIN; INTERFERON; IRINOTECAN; MITOMYCIN; MITOXANTRONE; PACLITAXEL; RECOMBINANT INTERLEUKIN 2; VINCRISTINE;

AGED; ARTICLE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMORBIDITY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; TREATMENT OUTCOME; UNITED STATES;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COHORT STUDIES; FEMALE; HUMANS; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MEDICARE; PALLIATIVE CARE; POPULATION SURVEILLANCE; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; SEER PROGRAM; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 84856439492     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318224d669     Document Type: Article

References (19)

1. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1973-2007), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2010, based on the November 2009 submission.
2. El Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003;139:817-823.
3. Altekruse SF, Kosary CL, Krapcho M, et al, SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/ 1975-2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010.
4. Davis GL, Alter MJ, El-Serag HB, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513-521.
5. Liu JH, Chen PW, Asch SM, et al. Surgery for hepatocellular carcinoma: does it improve survival? Ann Surg Oncol. 2004;11:298-303.
6. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429-442.
7. Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40:IV-18.
8. Klabunde CN, Warren JL, Legler JM. Assessing comorbidity using claims data: an overview. Med Care. 2002;40:IV-35.
9. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: John Wiley & Sons; 1989.
10. Bruix J, Llovet JM. Two decades of advances in hepatocellular carcinoma research. Semin Liver Dis. 2010;30:1-2.
11. Giannini EG, Bodini G, Corbo M, et al. Impact of evidencebased medicine on the treatment of patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther. 2010;31:493-501.
12. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734-1739.
13. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164-1171.
14. Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005;97:1532-1538.
15. Lai CL, Wu PC, Chan GC, et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma: a prospective randomized trial. Cancer. 1988;62:479-483.
16. Kim BK, Park JY, Choi HJ, et al. Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol. 2010;137:659-667.
17. Yang TS, Lin YC, Chen JS, et al. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer. 2000;89:750-756.
18. El Serag HB, Siegel AB, Davila JA, et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a populationbased study. J Hepatol. 2006;44:158-166.
19. Eckhoff DE, McGuire BM, Young CJ, et al. Race: a critical factor in organ donation, patient referral and selection, and orthotopic liver transplantation? Liver Transpl Surg. 1998;4:499-505.